Current Report Filing (8-k)
May 04 2016 - 8:35AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): May 4, 2016
ORAMED
PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel
|
|
91390
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
+972-2-566-0001
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
Oramed
Pharmaceuticals Inc. (the “Company”) expects to receive and announce results from its Phase 2b clinical trial for
its ORMD-0801 oral insulin capsule in approximately two weeks’ time.
The
double-blind, randomized Phase 2b trial of 180 patients with type 2 diabetes was conducted under a U.S. Food and Drug Administration
Investigational New Drug protocol at 33 clinical sites in the United States.
Warning
Concerning Forward Looking Statements
This
Current Report on Form 8-K (the “Report”) contains statements which constitute forward looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are
based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur
and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, the Report
states that the Company expects to receive and announce results from its clinical trial in approximately two weeks’ time.
In fact, the timing of the receipt of these results could change due to various factors and the receipt and announcement could
be delayed. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements.
Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to
reflect any event or circumstance that may arise after the date of the Report.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/ Nadav Kidron
|
|
Name:
|
Nadav Kidron
|
|
Title:
|
President and CEO
|
May
4, 2016
3
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024